TY - JOUR
T1 - Association of serum total bilirubin with renal outcome in Japanese patients with stages 3-5 chronic kidney disease
AU - Sakoh, Teppei
AU - Nakayama, Masaru
AU - Tanaka, Shigeru
AU - Yoshitomi, Ryota
AU - Ura, Yoriko
AU - Nishimoto, Hitomi
AU - Fukui, Akiko
AU - Shikuwa, Yui
AU - Tsuruya, Kazuhiko
AU - Kitazono, Takanari
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Objective Serum bilirubin has been reported to be associated with the progression of kidney disease in patients with diabetic nephropathy. Less is known, however, about the relationship between bilirubin and chronic kidney disease (CKD) of other etiologies. This study was designed to clarify whether serum total bilirubin concentration is associated with kidney disease progression in patients with CKD independent of etiology. Materials and methods This prospective observational study enrolled 279 consecutive patients with stages 3-5 CKD. The renal endpoint was the composite of the doubling of serum creatinine or end-stage renal disease requiring dialysis. Patients were divided into three groups by their serum total bilirubin concentrations: ≤0.3 (lowest), 0.4-0.5 (middle), and ≥ 0.6 (highest) mg/dL. A Cox proportional hazards model was applied to determine the risk factors for poor renal outcome. Results The median follow-up period was 21 months. One-hundred and three patients reached renal end points. After multivariable adjustment, a 0.1 mg/dL increase in serum bilirubin was associated negatively with poor renal outcome (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.87). In addition, after adjustment for confounding factors, including traditional and nontraditional cardiovascular risk factors, the middle (HR 3.14, 95% CI 1.36-8.57) and lowest (HR 4.22, 95% CI 1.81-11.59) bilirubin groups had significantly higher HRs for renal outcome than the highest bilirubin group. Conclusions Lower serum bilirubin concentration was independently associated with adverse renal outcomes, suggesting that the measurement of serum bilirubin is useful for predicting kidney disease progression in patients with moderate to severe CKD. ;copy; 2015 Elsevier Inc.
AB - Objective Serum bilirubin has been reported to be associated with the progression of kidney disease in patients with diabetic nephropathy. Less is known, however, about the relationship between bilirubin and chronic kidney disease (CKD) of other etiologies. This study was designed to clarify whether serum total bilirubin concentration is associated with kidney disease progression in patients with CKD independent of etiology. Materials and methods This prospective observational study enrolled 279 consecutive patients with stages 3-5 CKD. The renal endpoint was the composite of the doubling of serum creatinine or end-stage renal disease requiring dialysis. Patients were divided into three groups by their serum total bilirubin concentrations: ≤0.3 (lowest), 0.4-0.5 (middle), and ≥ 0.6 (highest) mg/dL. A Cox proportional hazards model was applied to determine the risk factors for poor renal outcome. Results The median follow-up period was 21 months. One-hundred and three patients reached renal end points. After multivariable adjustment, a 0.1 mg/dL increase in serum bilirubin was associated negatively with poor renal outcome (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.87). In addition, after adjustment for confounding factors, including traditional and nontraditional cardiovascular risk factors, the middle (HR 3.14, 95% CI 1.36-8.57) and lowest (HR 4.22, 95% CI 1.81-11.59) bilirubin groups had significantly higher HRs for renal outcome than the highest bilirubin group. Conclusions Lower serum bilirubin concentration was independently associated with adverse renal outcomes, suggesting that the measurement of serum bilirubin is useful for predicting kidney disease progression in patients with moderate to severe CKD. ;copy; 2015 Elsevier Inc.
UR - http://www.scopus.com/inward/record.url?scp=84939562298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939562298&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2015.06.006
DO - 10.1016/j.metabol.2015.06.006
M3 - Article
C2 - 26142826
AN - SCOPUS:84939562298
SN - 0026-0495
VL - 64
SP - 1096
EP - 1102
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 9
ER -